Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

High-Dose Chemotherapy Plus Transplant Not Recommended for DLBCL

July 13, 2017
By Leah Lawrence
News
Article

Patients with high-risk diffuse large B-cell lymphoma had a reduced risk of treatment failure, but no survival improvement, with an abbreviated course of rituximab-dose-dense chemotherapy plus high-dose chemotherapy and transplant compared with a full course of chemotherapy.

Patients with high-risk diffuse large B-cell lymphoma (DLBCL) had a reduced risk of treatment failure when assigned to an abbreviated course of rituximab-dose-dense chemotherapy plus high-dose cytarabine, mitoxantrone, and dexamethasone (R-MAD) plus carmustine, etoposide, cytarabine, and melphalan (BEAM) plus autologous stem cell transplantation compared with a full course of rituximab-dose-dense chemotherapy, according to a study published in Lancet Oncology. However, this treatment regimen did not result in an improvement in overall survival.

“On the basis of these results, early consolidation with high-dose chemotherapy and autologous stem cell transplantation cannot be recommended, and R-CHOP [rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone] should remain the standard treatment for DLBCL in patients with poor prognosis,” wrote Annalisa Chiappella, MD, of the department of hematology at Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino in Turin, Italy, and colleagues.

The study compared two different dose levels of R-CHOP: a full course of rituximab-dose-dense chemotherapy (no transplant group) compared with an abbreviated course of rituximab-dose-dense chemotherapy followed by consolidation with R-MAD and BEAM plus stem cell transplantation. The study included 399 patients age 18 to 65 years with untreated high-risk DLBCL. The patients were randomly assigned to one of four arms: R-CHOP delivered in a 14-day cycle (R-CHOP-14) for 8 cycles; high-dose R-CHOP-14 (R-MegaCHOP-14) for 6 cycles; R-CHOP-14 for 4 cycles followed by R-MAD plus BEAM and autologous stem-cell transplantation; or R-MegaCHOP-14 for 4 cycles followed by R-MAD plus BEAM and autologous stem cell transplantation. The primary endpoint was failure-free survival at 2 years.

With a median follow-up of 6 years, the 2-year failure-free survival rate for the whole population was 66%, the overall survival rate was 82%, and the progression-free survival rate was 69%. Patients assigned to transplant had significantly improved 2-year failure-free survival rates (71% vs 62%; hazard ratio [HR], 0.65; 95% CI, 0.47–0.91; P = .012) compared with patients who did not receive a transplant. However, there was no significant difference in 5-year overall survival between the transplant groups.

The researchers suggested several reasons why the difference in failure-free survival did not translate into a difference in overall survival as it has in other trials of DLBCL. First, this study did not include patients older than 65 years, suggesting that failure-free survival may not be a valid surrogate endpoint in this younger patient population. In addition, a difference in failure-free survival with transplant was only seen in patients with intermediate-high risk, which could have lowered the power of the comparison.

There was no significant difference in failure-free survival between patients who received R-CHOP-14 and R-MegaCHOP-14 (67% vs 66%). Based on this, the researchers wrote, “The findings do not support the hypothesis that increasing the dose of R-CHOP improves outcomes in patients with DLBCL who are at high risk.”

Grade 3 or worse hematologic events occurred in 92% of patients assigned to transplant and 68% of patients in the no-transplant group. The most common nonhematologic adverse event was gastrointestinal (25% of transplant patients vs 10% with no transplant).

“The addition of novel drugs such as lenalidomide, ibrutinib, bortezomib, and others to standard R-CHOP regimens has been reported in phase I or II studies with promising results in high-risk patients as well, leading to ongoing phase III randomized trials to assess the efficacy of these strategies,” the researchers noted. “While awaiting the results of these randomized studies, the standard treatment in patients with DLBCL at intermediate-high and high risk remains chemoimmunotherapy based on the standard R-CHOP regimen.”

Recent Videos
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
Symposiums and regional meetings may expand knowledge of how to adopt novel CAR T-cell therapies and bispecific antibodies, said Suman Kambhampati, MD.
Related Content
Advertisement

Two hematologic oncologists defined rare lymphomas and highlighted challenges and recent developments associated with these disease types.

Outlining Considerations for the Rare Lymphoma Treatment Paradigm

Roman Fabbricatore
October 17th 2025
Article

Two hematologic oncologists defined rare lymphomas and highlighted challenges and recent developments associated with these disease types.


Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.


The regulatory agency gave a PDUFA target action date of April 6. 2026 for Orca-T among patients with AML, ALL, and MDS.

FDA Grants Priority Review to BLA for Orca-T in Hematologic Malignancies

Roman Fabbricatore
October 6th 2025
Article

The regulatory agency gave a PDUFA target action date of April 6, 2026, for Orca-T among patients with AML, ALL, and MDS.


A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.


Data from the CADENZA trial support the application for pivekimab sunirine as a treatment for those with blastic plasmacytoid dendritic cell neoplasms.

FDA Receives BLA for Pivekimab Sunirine in Rare Hematologic Malignancy

Russ Conroy
October 1st 2025
Article

Data from the CADENZA trial support the application for pivekimab sunirine as a treatment for those with blastic plasmacytoid dendritic cell neoplasms.


A 13-week Good Laboratory Practice toxicity study demonstrated that UB-VV111 was well-tolerated in CD34-humanized mice.

FDA Grants Fast Track Designation to UB-VV111 in Select B-Cell Malignancies

Tim Cortese
October 1st 2025
Article

A phase 1 trial is evaluating UB-VV111 with and without rapamycin as treatment for patients with CLL and LBCL who received at least 2 prior therapies.

Related Content
Advertisement

Two hematologic oncologists defined rare lymphomas and highlighted challenges and recent developments associated with these disease types.

Outlining Considerations for the Rare Lymphoma Treatment Paradigm

Roman Fabbricatore
October 17th 2025
Article

Two hematologic oncologists defined rare lymphomas and highlighted challenges and recent developments associated with these disease types.


Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.


The regulatory agency gave a PDUFA target action date of April 6. 2026 for Orca-T among patients with AML, ALL, and MDS.

FDA Grants Priority Review to BLA for Orca-T in Hematologic Malignancies

Roman Fabbricatore
October 6th 2025
Article

The regulatory agency gave a PDUFA target action date of April 6, 2026, for Orca-T among patients with AML, ALL, and MDS.


A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.


Data from the CADENZA trial support the application for pivekimab sunirine as a treatment for those with blastic plasmacytoid dendritic cell neoplasms.

FDA Receives BLA for Pivekimab Sunirine in Rare Hematologic Malignancy

Russ Conroy
October 1st 2025
Article

Data from the CADENZA trial support the application for pivekimab sunirine as a treatment for those with blastic plasmacytoid dendritic cell neoplasms.


A 13-week Good Laboratory Practice toxicity study demonstrated that UB-VV111 was well-tolerated in CD34-humanized mice.

FDA Grants Fast Track Designation to UB-VV111 in Select B-Cell Malignancies

Tim Cortese
October 1st 2025
Article

A phase 1 trial is evaluating UB-VV111 with and without rapamycin as treatment for patients with CLL and LBCL who received at least 2 prior therapies.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.